GEROPHARM Group is the winner of the National import substitution award "Priority-2015"
The awarding ceremony of the nominees and winners of the National award in the field of import substitution "Priority-2015" was held in the atrium of the Pushkin State Museum of Fine Arts on December 9 in Moscow. GEROPHARM Group has become a prizewinner in the nomination "Pharmaceutical industry".
The main objective of the National award "Priority" is to provide assistance in the active development of import substitution in Russia as the largest world class goods and services supplier, to raise credibility towards local manufacturers, to increase demand for local products and technologies and to attract additional investment for production modernization and quality improvement of manufacturing products.
The contest was staged in the nominations corresponding to the main strategic directions of import substitution, set by the Government of the Russian Federation. All together there were 16 nominations, including the following fields: mechanical engineering, agriculture, chemical industry, high technologies, software, defense industry, pharmaceutical industry and other significant branches.
Relying on a number of important achievements in the pharmaceutical industry, GEROPHARM Group, the only Russian manufacturer of genetically engineered human insulins on the basis of full cycle principle, participated in the Award. The key element of GEROPHARM Group’s strategy is the saturation of the Russian market with the available local drug products of high quality. Having realized some successful projects on import substitution for the market, the company is actively investing in technological development and innovative infrastructure.
"I am glad that the achievements of all out team were highly appreciated," comments Petr Rodionov, the head of GEROPHARM Group. "Our own production technology of such vital drugs as insulins within the country is an indispensable condition for medicinal safety and the safety of all our citizens. Import substitution is not an end in itself, but one of the means to overcome the country’s vulnerability in technologies, professional competences and to create and strengthen the competitive advantages in all spheres. I am also glad that our team has made a considerable contribution to the development of pharmaceutical industry in Russia".
Having opened insulin manufacturing plant in the Moscow region in 2013, GEROPHARM Group has managed in two years to increase its substance production capacity and produce drugs in new modern delivery forms and also increase its market share significantly by means of optimized and intensified production processes. The created modern technological platform and the accumulated competences will give the company an opportunity introduce to the market a full pipeline of analogue insulins - lispro, aspart, glargin, degludec in the near future, in 2019.